Editorials
Treatment of 41r4 l oesophageal varicesa Patients with oesophageal varic reatment under two separate sets of circumstances. These are for the management of acute variceal bleeding and for treatment to prevent recurrent variceal bleeding after a previous haemorrhage. Treatment in both areas remains controversial.
In managing acute variceal bleeding it is essential to confirm that the haemorrhage is from oesophageal varices. Thus, emergency endoscopy is mandatory in all patients with massive upper gastrointestinal bleeding in whom bleeding varices are suspected. This will not only exclude patients who do not have oesophageal varices, but will also identify those patients with varices who are, in fact, bleeding from another source. In two prospective studies, one-third (Novis et al. 1976 ) and 18 of 64 patients (Terblanche et al. 1979a ) with endoscopically confirmed oesophageal varices, were bleeding from other sites.
The emergency medical management of patients with oesophageal variceal bleeding is reasonably well standardized (Terblanche et al. 1974) , and should include the use of fresh platelet rich blood and/or blood component therapy. The author's group use intravenous Pitressin (vasopressin), given as a bolus, in the early management of patients with suspected bleeding varices (Terblanche et al. 1974 , Novis et al. 1976 ). Even if variceal bleeding stops during Pitressin therapy, it frequently recurs. Recent evidence has suggested that continuous intravenous infusion of Pitressin might be superior (Barr et al. 1975 ) and that it is as effective as the more complex procedure of intraarterial infusion into the superior mesenteric artery (Johnson et al. 1977) .
Patients whose bleeding stops early during conservative treatment, and in whom bleeding does not recur, require no further emergency treatment. In a recent study, 22 of 46 consecutive patients admitted with bleeding oesophageal varices had stopped bleeding by the time of emergency endoscopy and bleeding did not recur. All survived the hospital admission (Terblanche et al. 1979a) . This is quite different from the high morbidity and mortality noted in patients who continue to bleed and require additional procedures. It is often difficult to predict the outcome of a bleed, but the risk grade (based on Child's classification or one of its modifications) (Novis et al. 1976 , Terblanche et al. 1979b ) and early cessation of bleeding are 0 141-0768/79/030163-04/$O 1.00/0 important. Recently, the level of portal pressure has been suggested as a useful prognostic factor (Adamsons et al. 1977) , but further studies are required to confirm this.
Despite contrary opinions (Conn & Simpson 1967) , a correctly used Sengstaken-Blakemore tube will arrest acute bleeding from varices in most patients (Pitcher 1971 , Novis et al. 1976 , Terblanche et al. 1979a ). The tube should only be inserted in those patients who continue to bleed and are shown to be actively bleeding from varices at the time of emergency endoscopy (Novis et al. 1976 , Terblanche et al. 1979a ). The author's group inflate both the gastric and the oesophageal balloons, although there is evidence that the oesophageal balloon may not provide the degree of compression previously believed (Agger et al. 1978) . Unfortunately, many patients rebleed on removal of the tube with an associated high mortality (Novis et al. 1976 ). Thus most patients requiring the Sengstaken-Blakemore tube to control haemorrhage need furthe.r treatment. The problem is to decide which treatment should then be used.
Although an emergency portacaval shunt will stop variceal bleeding, few authorities recommend the procedure today because of the high operative mortality. Orloff, the main proponent, had a 49% operative mortality in 138 consecutive patients (Orloff et al. 1975 ). An argument said to favour emergency shunting is that at 5 years there is little difference in survival in patients undergoing either emergency or elective portacaval shunts (Malt et al. 1978) . Other portosystemic shunts are seldom used in emergencies, except the mesocaval shunt. However, the operative mortality with the mesocaval shunt was higher than with the standard portacaval shunt in a randomized study (Malt et al. 1978) .
Various oesophagogastric devascularization procedures and direct operations to either transect this area, or underrun the varices, were advocated as emergency measures in the past. The high mortality, especially in poor risk alcoholic cirrhotic patients, has been of concern. Interest has been restimulated by encouraging recent reports. An extensive devascularization and transection procedure has been reported from Japan with remarkably good results (Sugiura & Futagawa 1977) . It seems unlikely that this truly massive operation will have as low a mortality in the types of patients seen in Western countries (Terblanche et al. 1979a ). The use of a stapling gun for oesophageal transection, with or without gastric devascularization, has been advocated as less hazardous and more successful than older techniques (Takasaki et al. 1977 , Johnston 1978 . Further experience is required to determine the true role of these procedures.
Either indirect or direct obliteration of the oesophageal varices themselves has the theoretical appeal of being a simple direct approach to managing actively bleeding varices. Indirect obliteration of varices using the percutaneous, transhepatic route was first proposed by Lunderquist & Vang (1974) . Although excellent results have been reported by Viamonte et al. (1977) , with cessation of bleeding in all 32 patients in which the technique was used for acute bleeding, it was successful in only 7 of 13 patients reported by Scott et al. (1976) , and the originators of the technique have drawn attention to a number of problems and have continued to modify the procedure (Lunderquist et al. 1977 , Lunderquist et al. 1978 .
Direct peroesophageal injection sclerotherapy was first reported 40 years ago (Crafoord & Frenckner 1939) . This was followed by a number of enthusiastic reports with one of the main proponents in the United Kingdom being Macbeth (1955) . However, with the widespread acceptance of portacaval shunting, and probably because the bulk of injection sclerotherapy literature appeared in otolaryngology journals, the procedure was infrequently used for almost two decades. Notable exceptions were the Belfast group (Johnston & Rodgers 1973 ) and a number of European workers (Paquet & Oberhammer 1978 , Kapp & Buess 1973 , Pinel et al. 1971 . The excellent results reported by Johnston & Rodgers (1973) have restimulated interest in the United Kingdom (Bailey & Dawson 1975) . In a large group of patients (217 injections in 117 patients), the Belfast workers controlled acute variceal haemorrhage in 9370 of admissions, with an injection mortality of under 12% and a total admission mortality of 18%. Paquet & Oberhammer (1978) , using a different technique, have reported 640 patients with 90% success in stopping acute bleeding or preventing recurrent bleeding in the succeeding 4 months. In a smaller experience, all patients admitted with massive upper gastrointestinal haemorrhage to a single hospital in Cape Town were assessed prospectively over a 25-month period. Sixty-four patients were shown to have oesophageal varices on emergency endoscopy. Twenty-four of these patients were actively bleeding from varices at the time of endoscopy and required the Sengstaken-Blakemore tube to control bleeding. Twenty-two were referred for injection sclerotherapy and have been followed prospectively. They had 51 episodes of variceal bleeding requiring 49 injections during 36 separate hospital admissions. By the combined use of the Sengstaken-Blakemore tube, followed by injection sclerotherapy, ultimate control of haemorrhage was achieved in 92% of hospital admissions with a 25% hospital mortality (Terblanche et al. 1979a ). This should be compared with the group's previous experience of the use of the Sengstaken-Blakemore tube alone, where there was a 60% rebleed rate on removal of the tube and a 60% in hospital mortality (Novis et al. 1976 ).
Furthermore, since commencing injection sclerotherapy, no patient has died primarily of continued variceal bleeding, and exsanguinating variceal haemorrhage no longer poses a major problem (Terblanche et al. 1979a) . In both these studies only the problem group of patients with continued variceal bleeding, requiring the Sengstaken-Blakemore tube for initial control of haemorrhage, were included.
One unresolved question is whether injection sclerotherapy is best performed by injecting the sclerosant directly into the varices (Macbeth 1955 , Johnston & Rodgers 1973 , Pinel et al. 1971 , Bailey & Dawson 1975 , Terblanche et al. 1979a ) causing thrombosis, or whether the sclerosant should be injected submucosally adjacent to the varix, thereby thickening the mucosa to prevent bleeding (Paquet & Oberhammer 1978 , Kapp & Buess 1973 . The author favours the former technique which, with recent modifications, is described in detail elsewhere (Terblanche et al. 1979a) .
Another unresolved question is whether a rigid or a flexible fibreoptic oesophagoscope should be used for injection sclerotherapy. The appeal of the fibreoptic scope is that injections can be performed without a general anaesthetic. However, the rigid scope used under general anaesthesia has distinct advantages. The modified 50 cm rigid Negus oesophagoscope is recommended (Bailey & Dawson 1975 , Terblanche et al. 1979a ). It has a proximal light source, which does not become obscured if bleeding occurs. Only one distended varix projects into the slot, which is situated at the distal end opposite the beak, thereby facilitating injection. At the same time the other variceal channels are compressed by the wide bore scope. After injection of the first varix, immediate rotation of the oesophagoscope compresses this varix, which promotes sclerosis, and prevents bleeding or loss of sclerosant from the needle-prick site. At the same time the next varix presents for injection. Thereafter the third and any additional varices are similarly individually injected while compressing the already injected varices (Terblanche et al. 1979a ). The fibreoptic scope, as presently designed, does not offer any of these advantages.
In the author's opinion, peroesophageal injection sclerotherapy is the best treatment available today for patients with continued oesophageal variceal bleeding who require a Sengstaken-Blakemore tube for initial control of haemorrhage.
Percutaneous transhepatic obliteration of varices is an alternative that requires further evaluation, particularly in a controlled trial comparing it with peroesophageal injection sclerotherapy. The results of the Lund trial are awaited with interest (Lunderquist et al. 1977) .
The second problem area in the management of patients with oesophageal varices is the long-term prevention of recurrent variceal bleeding, with its associated high morbidity and mortality. Analysis of the control groups of patients in the prospective trials ofportacaval shunts indicates that the chance of a recurrent bleed is 70% in patients who have had a previous variceal bleed, and the chance of a first bleed is under 30% in those patients with varices that have not yet bled (Conn 1974) . Although most authorities have accepted that there is a need to treat patients who have had a variceal bleed, one alternative that must be considered today is to manage such patients expectantly and treat recurrent variceal bleeds, when they occur, along the lines already indicated. This policy is supported by the data from recent controlled clinical trials, comparing therapeutic portacaval shunting with conservative medical management, as they have not shown significantly increased survival in the shunted patients (Jackson et al. 1971 , Resnick et al. 1974 , Rueff et al. 1976 .
Until recently conventional portacaval shunts, which prevent recurrent variceal bleeding, were considered the treatment of choice. Unfortunately, these shunts are associated with unpredictable adverse side effects, particularly chronic hepatic encephalopathy. Nevertheless, in the absence of better treatment, many authorities still consider shunting the best management for selected patients. The author does not subscribe to this view and believes that total portacaval shunts are seldom indicated today.
The selective distal splenorenal shunt (Warren shunt), which preserves mesenteric flow to the liver while decompressing varices, should theoretically be better than total shunting, although it is a technically more difficult procedure and cannot be used in all patients. It requires further long term evaluation, but has a low postoperative encephalopathy rate in selected patients (Rikkers et al. 1978) and is reported to have the highest postshunt survival rate in nonalcoholic cirrhotics (Zeppa et al. 1977) . Unanswered questions are whether variceal bleeding will recur and whether hepatopetal flow, with its theoretical advantage, will be lost as collateral channels open up. This fear has been borne out in the recent publication by Warren's group where over 50% of the patients have lost hepatopetal flow on long term follow up (Rikkers et al. 1978) . Another method of increasing the blood flow to the liver post-shunt is to arterialize the divided hepatic stump of the portal vein (Maillard et al. 1974 , Adamsons et al. 1978 . Although this does not provide portal blood it increases liver blood flow. Further evaluation is required to ensure that the high pressure in the liver produced by arterialization is not deleterious. Other shunt procedures include the mesocaval shunt popularized by Drapanas (1972) , the standard splenorenal shunt and makeshift shunts.
Devascularization and disconnection procedures have been used to prevent recurrent bleeds. The results have usually been disappointing as varices have recurred in time, and because these major operations cannot be repeated without undue risk to the patient. Some of the newer procedures described earlier have also been advocated in long-term management, but follow up is still too short to determine whether they will be any more effective.
As thrombosed vessels tend to recanalize, indirect or direct obliteration of varices should theoretically be of temporary benefit only. It is not yet known whether Gelfoam (absorbable gelatin sponge), with or without added sclerosants (Viamonte et al. 1977 , Lunderquist et al. 1977 , or tissue glue (Lunderquist et al. 1978 ), used to thrombose the coronary and short gastric veins by the percutaneous transhepatic route, will cause permanent occlusion. One group has reported a high recanalization rate (Lunderquist et al. 1977 , Lunderquist et al. 1978 . It also seems likely that other collateral channels will open up and that the submucosal varices in the lower oesophagus may again become a dangerous source of bleeding. Under these circumstances it may be technically difficult to repeat the procedure.
Repeated peroesophageal injection sclerotherapy has been used in the past to eradicate varices in patients considered unfit for definitive surgery such as portacaval shunting (Johnston & Rodgers 1973 , Paquet & Oberhammer 1978 . The preliminary results at 25 months in the first prospective controlled trial evaluating all patients who have bled from oesophageal varices, and comparing repeated injection sclerotherapy with conservative medical management, have been reported recently (Terblanche et al. 1979b) . Although too early to assess survival, it has been possible to eradicate oesophageal varices, and once the varices were eradicated, no patient has had a repeated bleed from varices. Thus in the short term varices can be eradicated and recurrent bleeding prevented. Longer follow up is required to determine how frequently reinjection will be required and whether recurrent bleeds will ultimately occur. However, reinjection is a simple procedure. An exciting finding was the complete disappearance of gross oesophageal and gastric varices in all the surviving patients treated by injection. On the other hand, many of the control patients continued to have recurrent life-threatening variceal bleeds (Terblanche et al. 1979b ). Even if repeated injection sclerotherapy does not ultimately prove to be the best treatment for all patients who have bled from oesophageal varices, it certainly provides a simple alternative treatment for patients unsuitable for shunting or other major surgery.
Thus, at present there are no clear guidelines as to the best treatment for a patient who has had a bleed from oesophageal varices. The options are conventional medical management, treating individual variceal bleeds as they occur, or some form of surgical or other treatment aimed at preventing recurrent variceal bleeds. Amongst the portosystemic shunts, the selective distal splenorenal shunt, and perhaps total portacaval shunting with arterialization of the liver, seem to offer the best promise, but require further detailed evaluation. Devascularization and disconnection procedures are unlikely to be of long-term benefit. The same will probably apply to percutaneous transhepatic obliteration of varices, which, in theory, will be difficult to repeat if the main coronary and short gastric veins remain occluded and other collateral channels open up. Repeated injection sclerotherapy also requires a longer period of evaluation, but is a simple alternative form of treatment and might even turn out to be the best long-term treatment. Its use does not preclude a subsequent shunt using any of the current techniques. On the other hand, percutaneous transhepatic obliteration of varices, if adequately performed by occluding both the coronary and short gastric veins, does preclude a Warren shunt. John Terblanche Professor of Surgery University of Cape Town Medical School Cape Town, South Africa
